Comparative Pharmacology
Head-to-head clinical analysis: CARAC versus EFUDEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARAC versus EFUDEX.
CARAC vs EFUDEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carac (fluorouracil) is a fluorinated pyrimidine antimetabolite that inhibits thymidylate synthase, thereby interfering with DNA synthesis and repair. It also incorporates into RNA, disrupting RNA processing and function.
Fluorouracil (5-FU) is a pyrimidine analog that inhibits thymidylate synthase, leading to depletion of thymidine triphosphate and disruption of DNA synthesis. It is incorporated into RNA as a false metabolite, interfering with RNA processing and function.
Apply 0.5% cream twice daily for 2-4 weeks to affected area; maximum single dose 1g, not exceed 60g per course.
For actinic keratosis: Apply topically to lesions twice daily for 2-4 weeks. For superficial basal cell carcinoma: Apply 5% cream twice daily for 3-6 weeks. Not for systemic use.
None Documented
None Documented
Terminal elimination half-life is approximately 20 minutes for the parent drug, but the active metabolite 5-fluorouracil (5-FU) has a half-life of 8–20 minutes; due to rapid metabolism, prolonged exposure occurs with continuous infusion.
Terminal half-life is approximately 16 minutes (range 8-20 min) for parent drug; clinical context: due to rapid metabolism, continuous infusion or frequent dosing is required for sustained antimetabolite effect.
Primarily metabolized via dihydropyrimidine dehydrogenase (DPD) in the liver; ~10% excreted unchanged in urine; remaining metabolites eliminated renally (including CO2 and urea).
Primarily hepatic metabolism to inactive metabolites; <15% excreted unchanged in urine; biliary/fecal excretion accounts for ~15%.
Category C
Category C
Topical Antineoplastic
Topical Antineoplastic